Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2production and Foxp3 expression

In vivostudy of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice

(2013) Meihua Jin et al.   DRUG DELIVERY

Management of recurrent cervical cancer: A review of the literature

(2012) M. Peiretti et al.   SURGICAL ONCOLOGY-OXFORD

The imbalance of Th17/Treg in patients with uterine cervical cancer

(2011) Yan Zhang et al.   CLINICA CHIMICA ACTA

The Effects of Artesunate on the Expression of EGFR and ABCG2 in A549 Human Lung Cancer Cells and a Xenograft Model

(2011) Hu Ma et al.   MOLECULES

Immunotherapy for Cervical Cancer

(2010) Jun-Han Su et al.   BIODRUGS

Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer

(2009) Christoph Loddenkemper et al.   CANCER SCIENCE

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

(2009) A. Greenhough et al.   CARCINOGENESIS

Host immune responses to cervical cancer

(2009) Swati Patel et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells

(2008) Michaël Herfs et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells

(2008) Jung-Min Oh et al.   CARCINOGENESIS

Progress in research on the anti-tumor effect of artesunate

(2008) Rong-rong He et al.   Chinese Journal of Integrative Medicine